<DOC>
	<DOCNO>NCT01695083</DOCNO>
	<brief_summary>Abstract : Fatty liver frequently correspond fat overload liver . It usually classify alcoholic steatosis non-alcoholic steatosis . In case non alcoholic fatty liver overload , histological spectrum range simple steatosis steatohepatitis ( NASH ) associate inflammation steatosis , risk progression fibrosis cirrhosis . Obese patient particular risk NASH . Screening hepatic lesion difficult especially may exist liver test normal . The diagnosis NASH currently do liver biopsy , expose particular risk hemorrhagic complication . Objectives : The main objective study determine patient morbid obesity wait bariatric surgery , accuracy non-invasive test assess liver steatosis , fibrosis inflammation diagnosis NASH , take reference liver biopsy morphometric study parameter . Inclusion criterion : Patients follow criterion eligible study : - Age ≥ 18 year - BMI ≥ 35 kg/m2 - Bariatric surgery schedule within 3 month follow inclusion - Signature informed consent Non-inclusion criterion : Patients least one follow criterion eligible study - Patient non-affiliated social security scheme ( beneficiary assignee ) - Contra-indication performing MRI - weight &gt; 230 kg ; anteroposterior diameter &gt; 40 cm - Cancer treatment medication may induce lesion steatohepatitis ( corticoid , methotrexate , amiodarone , perhexiline , tamoxifen , nifedipine , diltiazem , hycanthone ) - Alcohol consumption &gt; 20 g per day woman &gt; 30 g per day men AND past history excessive alcohol use 2-year period within last 20 year - Known chronic liver disease ( except steatosis ) : presence HBs antigen , antibody HCV , anti-nuclear antibody , anti-mitochondria , anti-LKM1 , anti-smooth muscle negative , presence hemochromatosis , - Known HIV positive status - Pregnant ( know pregnancy ) lactate woman Number subject require : According literature data collect Louis Mourier recent year , inclusion 200 patient would examine 20-40 patient severe histological steatosis steatohepatitis . All patient include Louis Mourier hospital . Follow-up : one month Search duration : 37 month Duration inclusion : 36 month The total duration participation patient one month . Methodology : It monocentric , prospective study evaluate value noninvasive test diagnosis hepatic lesion morbid obese patient . The `` open `` MRI system allow access MRI obese patient ( maximum weight 250 kg ) . Three system available France liver pathology explore system Louis Mourier . The reference method liver histology ; study test abdominal MRI , Fibroscan / CAP , serum test . Examinations require specifically research Examinations require specifically research abdominal MRI , FibroScan/ CAP serum test . Primary endpoint : To validate use abdominal MRI , FibroScan/ CAP serum test find severe steatosis / NASH , specificity , sensitivity , positive negative predictive value test calculate . The gold standard result histology liver biopsy , morphometric study parameter . ROC curve use determine best compromise sensitivity specificity . The secondary endpoint : Histological lesion liver fibrosis . Quantification abdominal fat MRI ( form three variable interest : quantification surface visceral fat , subcutaneous fat intrahepatic fat assess percentage loss signal</brief_summary>
	<brief_title>Non Invasive Measurements Fibrosis , Inflammation Steatohepatitis Morbidly Obese Patients</brief_title>
	<detailed_description>Main objective : The main objective study determine patient morbid obesity wait bariatric surgery , accuracy non-invasive test diagnosis severe steatosis / NASH . The gold standard liver biopsy morphometric study . Non-invasive test use : - Serum test : FibroMax ( include NASH test , FibroTest SteatoTest ) FibroMeter . - Radiological examination : MRI FibroScan / CAP Secondary objective : The secondary objective : 1. determine accuracy non-invasive test diagnosis severe steatosis alone , steatohepatitis ( NASH ) hepatic fibrosis 2. determine best combination test well evaluate presence severe steatosis , NASH hepatic fibrosis . 3. quantify MRI visceral subcutaneous fat morbidly obese patient Research Design : 1 . Judging Criteria Primary endpoint To validate use serum test , FibroScan / CAP abdominal MRI diagnosis severe steatosis / NASH ( specificity , sensitivity , positive negative predictive value ) . The gold standard result histology liver biopsy , morphometric study . For diagnostic test , ROC curve use determine best compromise sensitivity specificity . The histological diagnosis severe steatosis define presence hepatic steatosis grade 3 high . The diagnosis NASH define presence lobular inflammation neutrophil hepatocytes balloon . Secondary endpoint - Histological lesion liver fibrosis Quantification abdominal fat MRI ( form three variable interest : quantification surface visceral fat surface subcutaneous fat amount intrahepatic fat assess percentage loss signal ) . 2 . Methodology expect number patient research This prospective study evaluate value noninvasive test diagnosis hepatic lesion morbid obese patient . The MRI system `` open '' allow access obese patient . Three system available France liver pathology support system Louis Mourier . The reference method liver histology ; test study MRI abdominal Fibroscan / CAP , serum test ( FibroTest , FibroMeter , SteatoTest , NASH test ) . The study conduct 200 obese patient liver biopsy perform bariatric surgery : - Tests detection steatosis ( fat quantification intrahepatic MRI measurement steatosis CAP , serum test ) evaluate histological steatosis ( main objective ) - Tests detection NASH ( test serum ) histology - Tests fibrosis ( serum test ; FibroScan ) histological data assess fibrosis . The duration extent obesity ( BMI ) biological data ( HOMA-test ) take account . 3 . Examinations require specifically research Liver biopsy routinely perform intraoperatively routine monitoring patient bariatric surgery , examination specific research : - Serum test - FibroScan / CAP - Abdominal MRI Risk / risk absences The sting blood sampling cause formation small hematoma without gravity , subside spontaneously within day . FibroScan ® / CAP present risk side effect . Liver MRI show risk cons-indications respect . Wearing stack ( pacemaker ) element contain iron near eye head contra-indications major risk factor ( risk death , blindness ) . The presence heart valve stent ( also call metal prosthesis ) absolute contra-indication-and compatibility MRI verify completion examination , case practice clinic .. Liver biopsy , part examination carry systematic way without protocol add additional risk surgical 4 . Study site The study conduct Louis Mourier , reference center treatment obesity , open system allow access obese . 5 . Indications bariatric surgery Indications bariatric surgery Louis Mourier , reference center treatment obesity , consistent recommendation HAS 2009 , base professional consensus . Surgery indicate patient follow criterion : 1 . BMI ≥ 40 BMI ≥ 35 comorbid 2. failure ( ) prior ( ) conventional treatment obesity combine dietary , physical activity behavioral therapy 3. appraisal nutritionally : global , personal non-surgical 4. consider medical treatment minimum 1 year 5. well-informed motivated patient , acceptable surgical risk 6. obesity stable ( worsen ) five year 7. absence endocrine pathology ( adrenal , thyroid ) may due obesity</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Age ≥ 18 year BMI ≥ 35 kg/m2 Bariatric surgery schedule within 3 month follow inclusion Conducting medical examination . Signature informed consent Patient nonaffiliated social security scheme ( beneficiary assignee ) Consindication perform MRI weight &gt; 230 kg , anteroposterior diameter &gt; 40 cm Cancer treatment medication may induce lesion steatohepatitis ( corticoid , methotrexate , amiodarone , perhexiline , tamoxifen , nifedipine , diltiazem , hycanthone ) Alcohol consumption &gt; 20 g per day woman &gt; 30 g per day men AND past history excessive alcohol use 2year period within last 20 year know chronic liver disease steatosis ( presence HBs antigen , antibody HCV , antinuclear antibody , antimitochondria , antiLKM1 , antismooth muscle negative , presence hemochromatosis ) , know HIV positive status Pregnant woman ( known pregnancy ) lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Non alcoholic steatohepatitis</keyword>
	<keyword>Liver fibrosis , Steatosis</keyword>
	<keyword>Liver inflammation</keyword>
	<keyword>Morbid obesity</keyword>
	<keyword>Non invasive test</keyword>
</DOC>